Navigation Links
Major EPSRC Programme Grant to support new Oxford Centre for Drug Delivery Devices
Date:5/23/2014

Cancer therapy drugs tend to achieve limited accumulation and poor penetration in tumours, reducing their effectiveness. For many years, the only methods used to improve drug uptake by tumours have been pharmacological, and these have had limited success.

Recent research at Oxford University has shown that physical mechanisms triggered by ultrasound, magnetic fields or shock waves can dramatically improve the delivery and penetration of existing and experimental drugs into tumours.

Now a new research centre, The Oxford Centre for Drug Delivery Devices (OxCD3), will look to exploit engineering approaches, involving a combination of stimulus- responsive nanocarriers and medical devices already in clinical use, to improve the therapeutic outcomes of drug-based cancer treatments.

The new centre will be based at the University of Oxford and has been made possible by a 10.1 million Programme Grant which includes 6.4 million from the Engineering and Physical Sciences Research Council (EPSRC).

Led by Professors Coussios, Stride, Carlisle and Cleveland in the Institute of Biomedical Engineering, OxCD3 represents a partnership between the Department of Engineering Science, the Department of Oncology (Professors Seymour, Sibson and Vallis), the MRC Weatherall Institute of Molecular Medicine (Prof. Rabbitts), the Nuffield Department of Surgical Science (Prof. Friend) and the Clinical Biomanufacturing Facility (Dr Moyle).

The principal investigator, Professor Constantin Coussios, said: "We are very grateful to EPSRC, our industrial partners and the University of Oxford for their support of OxCD3. This will enable the creation of a sustainable, world-‐ unique multi-‐disciplinary environment for combinational engineering of biology, chemistry and medical devices to improve drug delivery under a single roof. It is also expected to create a much-‐needed training environment for the next generation of young scientists working on combination therapies and biomedical nanotechnology, by providing direct exposure to regulatory and manufacturing issues encountered when translating laboratory research into production and clinical practice."

The new Centre will initially focus on improving the delivery of several classes of cancer drugs, ranging from conventional chemotherapy and radiopharmaceuticals to next-‐generation antibodies, viruses and siRNA, from proof-of-concept laboratory studies to manufacture in preparation for clinical trials. The ultimate aim is to establish a centre of excellence for challenging drug delivery applications across a broad range of biological barriers and disease indications beyond cancer.


'/>"/>

Contact: EPSRC Press Office
pressoffice@epsrc.ac.uk
01-793-444-404
Engineering and Physical Sciences Research Council
Source:Eurekalert

Related medicine news :

1. Therapy sought to reduce major risk from minor bleeding that can follow stroke
2. Major lung resection safer than ever, especially at the busiest hospitals
3. Genetic alterations in shared biological pathways as major risk factor for ASD
4. Gen X obesity a major problem for healthcare, workforce
5. Surgery after major stroke also improves survival odds in elderly patients
6. A majority prefers letting computers decide
7. Major third-hand smoke compound causes DNA damage -- and potentially cancer
8. Patient requests for specific drugs have major impact on prescribing, reports study in Medical Care
9. Major League Baseball players win more games following Tommy John surgery
10. NYU researchers find majority of Latinas are unaware of their risk of diabetes
11. International study shows majority of children unaware of cigarette warning labels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... will be speaking on how healthcare companies can use newly released government data ... health of a population and intervene and capture the value they create to ...
(Date:2/7/2016)... , ... February 07, 2016 , ... Women's Excellence staff, ... Wear Red Day. National Wear Red Day is the first Friday each February ... disease and stroke cause 1 in 3 deaths among women each year – more ...
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... With the ... easily add warm color grades to their footage. A LUT is a Lookup Table ... color to the corresponding color indicated by the table. By manipulating each pixel, LUT's ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... availability of the company's lighter, sleeker next generation LYNX VR Indoor Trainer with ... , Improvements in design and manufacturing not only reduce the weight of the ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology: